A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2025-11-01
Target enrollment:
Participant gender:
Summary
This phase II study is designed to investigate the efficacy and safety of BL-B01D1
monotherapy, SI-B003 monotherapy, and BL-B01D1+SI-B003 combination therapy in patients with
extensive-stage small cell lung cancer.